Skip to main content Skip to search Skip to main navigation

EMA: Multi-factor Authentication for CTIS Mandatory by June

From 1 June 2023 multi-factor authentication (MFA) will be introduced for user login to CTIS (Clinical Trials Information System) for both sponsors and Member States. This should significantly increase user account security.

To prepare for MFA, each user will need to be equipped with an additional mobile or work phone. Registration and setup are already available on the EMA's ServiceNow portal. This will also be directly functional for the CTIS system. More information about the activation process can be found here. The CTIS Training Environment does not require any additional authorisation steps. Since the launch of CTIS in January 2022, more than 1000 applications for initial clinical trials have been submitted. More than 400 clinical trials have been approved under the Clinical Trials Regulation (CTR) and made available in the system.

Please note:
On 30 January 2025, all ongoing studies that have been approved according to the "old" Clinical Trials Directive will fall under the now applicable CTR (Clinical Trials Regulation (EU) No. 536/2014). From this date onwards, ongoing trials will also have to be transferred to the CTIS system.


EMA: Clinical Trials Highlights

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

In their „Horizon Scanning Report“, EMA and HMA have recommended updates to the regulatory framework to keep pace with developments in radiopharmaceuticals. Due to their unique characteristics these products require specific regulatory and scientific approaches.
Read more
How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:
Read more
Previous
Next